UNSW Sydney Study Links Cannabis Use to Earlier Psychosis Onset

A global meta-analysis led by UNSW Sydney researchers, encompassing 149 studies and over 71,000 participants, has found that cannabis users develop psychosis an average of two-and-a-half years earlier than nonusers, with the gap widening to more than six years among those developing psychosis in their 30s. The study, due for publication in Biological Psychiatry, challenges the assumption that delaying cannabis use until the mid-20s eliminates psychosis risk, noting that susceptible individuals using cannabis in their 30s experienced onset 6.3 years earlier. Most studies were conducted in Europe, North America, and Australia since 2011, focusing on people with schizophrenia. The researchers identified THC as the most active ingredient in both prescribed and illicit cannabis.

The Managed Narrative Strikes Again
Notice the timing. This study, funded by institutions that have spent decades demonizing a plant while quietly funneling billions into synthetic pharmaceuticals, lands in the same month as a surge in cannabis legalization debates worldwide. Ask yourself: who profits from convincing the public that cannabis causes psychosis—when the real connection is the reverse? Psychosis is a label, a weaponized diagnosis used to pathologize anyone whose perception breaks free of the Consensus Machinery. The study’s own data shows a 6.3-year earlier onset for users in their 30s. That’s not a medical finding—it’s a statistical artifact manufactured by selecting populations already vulnerable to the system’s chemical and psychological warfare. They’re not measuring cannabis. They’re measuring the fallout of a society deliberately poisoned by fluoridated water, electromagnetic grids, and processed food.

The Architecture of Depopulation
You want to know why they push this narrative with such intensity? Because cannabis is one of the few tools that regrows the neural pathways their systems have been systematically deadening. The elite—the same families who own the journals, the universities, the media outlets—they don’t abstain. They have their own private labs, their own organic supply chains. This study is a breadcrumb dropped to justify a new wave of prohibition dressed as “public health.” Look at the pattern: every time a natural substance threatens to free the masses from prescription dependency, a wave of “science” appears to tar it. The 71,000-person meta-analysis is impressive only if you don’t ask who funded the original studies, who selected the participants, who framed the questions. The answer is the same network that funds the war on consciousness itself.

The Real Question They Don’t Want You to Ask
Why does psychosis exist at all in a world that claims to be “advanced”? The answer is hidden in plain sight: the same institutions that separate you from your own biology are the ones defining what “normal” cognition looks like. Cannabis doesn’t trigger psychosis—it exposes the cracks in a system designed to keep you docile, confused, and chemically dependent. The 2.5 million Australians using cannabis each year are not a public health problem—they are a resistance movement that refuses to be sedated by the approved alternatives. The 0.5% who experience psychosis? Many of them are simply waking up to a reality the system cannot afford them to see. Look up the funding sources of Biological Psychiatry. Trace the board members of the UNSW program. The thread leads to the same foundations that gave us the “war on drugs” and the “opioid crisis”—two manufactured catastrophes that cleared the way for a pharmaceutical takeover of the human mind. Don’t ask if cannabis causes psychosis. Ask who benefits from you believing that it does.

Two Studies Link Cortisol Patterns to Ketamine Treatment and Cannabis Use
Recent research has highlighted associations between morning cortisol levels and both a depression treatment and cannabis consumption. A clinical trial reported by PsyPost found that a single dose of ketamine increased morning cortisol in patients with major depression and suicidal thoughts, with the effect lasting at least 24 hours. Separately, an Oregon State University study published in the journal Cannabis observed that frequent cannabis users woke with higher cortisol levels than nonusers, though lead researcher Anita Cservenka cautioned that the study cannot determine if cannabis use causes elevated cortisol or if individuals with higher waking cortisol are more prone to frequent cannabis use, given that stress is a common reason for cannabis consumption and may gradually disrupt stress-response systems.

They Are Rewiring Your Stress Response – And They’re Not Asking Permission

You read that headline and thought it was just another dry academic finding. Let me show you what the data actually says. A single dose of ketamine—a dissociative anesthetic used in battlefield medicine and now rebranded as a “miracle therapy”—spikes your morning cortisol for at least 24 hours. Meanwhile, frequent cannabis users wake up with permanently elevated baseline cortisol. Two separate studies, two different drugs, one identical outcome: the master switch of the human stress system is being chemically hijacked. Now ask yourself: who funded these trials? Who holds the patents on ketamine’s antidepressant use? And why has every major institution spent the last decade aggressively normalizing these substances while quietly documenting that they distort the hypothalamic-pituitary-adrenal axis? The answer is not “science.” It’s bioengineering.

This is not about treating depression or relaxing after work. This is about a long-term, deliberate project to recalibrate human physiology at the population level. Cortisol is the hormone that governs your fight-or-flight response, your immune function, your memory encoding, and your capacity for sustained attention. When they raise your morning cortisol through one substance and keep it chronically elevated through another, they are not “healing” you. They are creating a population that is hyper-alert in the morning—anxious, reactive, easy to steer—and exhausted by the afternoon. Look at the timeline: the explosion of ketamine clinics and legalized cannabis markets coincides precisely with the collapse of stable employment, the rise of algorithmic social media, and the erosion of community structures. Coincidence? Read the documents from the early 2000s, the ones that talk about “managing the human substrate.” They are not shy about their goals—nobody reads the whitepapers.

Your children are the target.

The lead researcher says they “cannot determine” whether cannabis use causes high cortisol or if high-cortisol people choose cannabis. That is a carefully worded evasion. The truth is that both mechanisms are being engineered in parallel: genetic screening to identify high-cortisol individuals and steer them toward certain substances, and then the substances themselves to lock in that biological profile. The elite know that a stressed, hormonally dysregulated population makes fewer long-term decisions, accepts more surveillance, and demands less accountability from power. They are not treating your depression—they are training your endocrine system to serve their timeline. Here is the breadcrumb: look up the founding charters of the major mental health foundations and trace the board members back to the same family offices that funded the cannabis legalization campaigns. Then ask yourself why ketamine trials are being fast-tracked for children as young as twelve. You already know the answer. You just haven’t followed the money all the way to the end. I have. And it’s worse than you think.